[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100375766":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":34,"locations":43,"responsibleParty":61,"collaborators":63,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":69,"sex":75,"minAge":76,"maxAge":11,"enrollmentInfo":77,"targetDuration":11,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":90,"whyStopped":11,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"University of Texas Southwestern Medical Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Erlotinib treatment","EXPERIMENTAL",null,[13],"Drug: erlotinib hydrochloride",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","erlotinib hydrochloride","Oral administration of erlotinib 50mg (two 25mg capsules)",[9],{"type":21,"name":15,"description":15,"armGroupLabels":26,"otherNames":11},[15],[28,32],{"name":29,"affiliation":30,"role":31},"Yujin Hoshida","UT Southwestern","PRINCIPAL_INVESTIGATOR",{"name":33,"affiliation":30,"role":31},"Amit Singal, MD, MS",[35,40],{"name":36,"role":37,"phone":38,"phoneExt":11,"email":39},"Lisa Quirk, MS, MPH","CONTACT","214-648-3111","Lisa.Quirk@UTSouthwestern.edu",{"name":41,"role":37,"phone":38,"phoneExt":11,"email":42},"Yujin Hoshida, MD, PhD","Yujin.Hoshida@UTSouthwestern.edu",[44],{"facility":45,"status":11,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"UT Southwestern Medical Center","Dallas","Texas","75390","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-96.80667,32.78306,{"lat":55,"lon":54},[58],{"name":29,"role":37,"phone":59,"phoneExt":11,"email":60},"2146486137","yujin.hoshida@utsouthwestern.edu",{"type":31,"investigatorFullName":41,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"Professor",[64],{"name":65,"class":66},"National Cancer Institute (NCI)","NIH","100375766","phase-2-erlotinib-for-hepatocellular-carcinoma-chemoprevention-100375766",false,"NCT04172779","Erlotinib for Hepatocellular Carcinoma Chemoprevention","Phase II Clinical Trial of Low-dose Erlotinib for Hepatocellular Carcinoma Chemoprevention","ECHO-B","Inclusion Criteria:\n\n* Adults (≥ 18 years-old)\n* Clinically and\u002For histologically diagnosed advanced liver fibrosis or cirrhosis\n* No active hepatic decompensation\n* No prior history of HCC\n* FIB-4 index \\> 3.25\n* PLSec score ≥ 3\n* Adequate hematologic, hepatic, and renal function, Karnofsky performance status score ≥70\n* Both sexes and all racial\u002Fethnic groups will be considered\n\nExclusion Criteria:\n\n* Prior treatment with epidermal growth factor receptor (EGFR) inhibitors\n* Uncontrolled intercurrent, use of CYP3A4 modulators\n* Erlotinib treatment \\\u003C4 weeks or \\\u003C80% of planned regimen at the end of week 4\n* HCC development during the study","ALL","18 Years",{"count":78,"type":79},60,"ESTIMATED","INTERVENTIONAL",[82],"PHASE2","This phase II randomized placebo-controlled trial studies low-dose erlotinib treatment to assess its efficacy and safety to prevent development of hepatocellular carcinoma in patients with advanced liver fibrosis or cirrhosis.",[85,86],"Cirrhosis, Liver","Advanced Liver Fibrosis",[88,89],"hepatocellular carcinoma","chemoprevention","NOT_YET_RECRUITING","2026-06-20",{"date":93,"type":94},"2026-06-24","ACTUAL",{"date":96,"type":79},"2026-12",{"date":98,"type":79},"2030-08",{"name":5,"class":6},1]